There isn't a day that goes by on Wall Street when certain stocks trading for under $10 a share don't experience massive spikes higher. Traders savvy enough to follow the low-priced names and trade them with discipline and sod risk management are banking ridiculous coin on a regular basis.

Just take a look at some of the big movers to the upside in the under-$10 complex from Thursday, including EnteroMedics (ETRM , which is exploding up 94%; Education Management (EDMC , which is ripping higher by 48%; Prana Biotechnology (PRAN , which is soaring by 37%; and Fibrocell Science (FCSC , which is surging by 26%. You don't even have to catch the entire move in lower-priced stocks such as these to make outsized returns when trading.

Low-priced stocks are something that I tweet about on a regular basis. These are also the exact type of stocks that I love to trade and alert in real time. I frequently flag high-probability setups, breakout candidates and low-priced stocks that are acting technically bullish. I like to hunt for low-priced stocks that are showing bullish price and volume trends, since that increases the probability of those stocks heading higher. These setups often produce monster moves higher in very short time frames.

When I trade under-$10 stocks, I do it almost entirely based off of the charts and technical analysis. I also like to find under-$10 stocks with a catalyst, but that's secondary to the chart and volume patterns.

With that in mind, here's a look at several under-$10 stocks that look poised to potentially trade higher from current levels.

Adaptimmune Therapeutics

One under-$10 clinical-stage biopharmaceutical player that's starting to trend within range of triggering a near-term breakout trade is Adaptimmune Therapeutics (ADAP - Get Report) , which focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. This stock has been hit hard by the sellers over the last six months, with shares dropping sharply by 53.4%.

If you take a look at the chart for Adaptimmune Therapeutics, you'll notice that this stock has recently formed a double bottom chart pattern, after shares found some buying interest at $3.76 to $3.85 a share over the last month. Following that potential bottom, this stock has now started to trend higher and move back above its 20-day moving average of $4.04 a share with decent upside volume flows. That spike higher has now pushed shares of Adaptimmune Therapeutics within range of triggering a near-term breakout trade.

Market players should now look for long-biased trades in Adaptimmune Therapeutics if it manages to break out above its 50-day moving average of $4.38 a share and then above some more near-term resistance levels at $4.40 to $4.50 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 167,760 shares. If that breakout fires off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $5 to $5.30, or even $5.75 to $6.40 a share.

Traders can look to buy this stock off weakness to anticipate that breakout and simply use a stop that sits right around those recent double bottom support levels. One can also buy shares of Adaptimmune Therapeutics off strength once it starts to trend above those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Proteon Therapeutics

Another under-$10 biotechnology player that's starting to move within range of triggering a big breakout trade is Proteon Therapeutics (PRTO , which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. This stock has been destroyed by the sellers over the last six months, with shares collapsing by 75.7%.

If you take a glance at the chart for Proteon Therapeutics, you'll notice that this stock recently gapped-down sharply lower from around $10 a share to under $2.50 a share with monster downside volume flows. Following that move, shares of Proteon Therapeutics went on to print a new 52-week low at $1.75 a share within a few weeks. This stock has now started to rebound off that $1.75 low and it's beginning to trend within range of triggering a big breakout trade above some key overhead resistance levels.

Traders should now look for long-biased trades in Proteon Therapeutics if it manages to break out above some near-term overhead resistance levels at $2.14 to $2.25 a share with volume that registers near or above its three-month average action of 208,676 shares. If that breakout develops soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $2.60 to its gap-down-day high from last December at $3.10 a share. Any high-volume move above $3.10 will then give this stock a chance to re-fill some of its gap-down-day zone that started near $10 a share.

Traders can look to buy this stock off weakness to anticipate that breakout and simply use a stop that sits right below some near-term support at $1.90 a share, or near its new 52-week low of $1.75 a share. One can also buy shares of Proteon Therapeutics off strength once it starts to move above those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Endologix

Another under-$10 healthcare player that's starting to spike within range of triggering a big breakout trade is Endologix (ELGX - Get Report) , which develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the U.S. and internationally. This stock has been smashed lower by the bears over the last six months, with shares dropping sharply by 53.2%.

If you look at the chart for Endologix, you'll notice that this stock has been downtrending badly over the last three months, with shares falling sharply off its high of $13.30 a share to its new 52-week low of $4.78 a share. During that downtrend, shares of Endologix have been making mostly lower highs and lower lows, which is bearish technical price action. That said, this stock has now started to rebound off that $4.78 low with strong upside volume flows. That high-volume bounce is now quickly pushing this stock within range of triggering a big breakout trade above some key overhead resistance levels.

Market players should now look for long-biased trades in Endologix if it manages to break out above some near-term overhead resistance levels at $6.45 to its 20-day moving average of $6.46 a share and then above more resistance at $6.55 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 2.13 million shares. If that breakout kicks off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $7.30 to $7.40, or even its 50-day moving average of $7.86 to $7.91 a share. Any high-volume move above $7.91 will then give this stock a chance to re-fill some of its previous gap-down-day zone from last November that started near $10 a share.

Traders can look to buy Endologix off weakness to anticipate that breakout and simply use a stop that sits right below some near-term support at $5.45 a share. One can also buy this stock off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Ophthotech

One under-$10 biopharmaceutical player that's starting to move within range of triggering a big breakout trade is Ophthotech (OPHT , which develops novel therapeutics to treat diseases of the back of the eye. This stock has been annihilated by the bears over the last six months, with shares plunging lower by 90.5%.

If you take a glance at the chart for Ophthotech, you'll notice that this stock recently gapped-down sharply lower from around $40 a share to $5 a share with monster downside volume flows. Following that move, shares of Ophthotech went on to print a new 52-week low of $4.53 a share, and subsequently trade sideways between $4.53 on the downside and $5.28 on the upside. This stock has now started to spike a bit higher off its recent low and it's beginning to trend within range of triggering a big breakout trade above the upper-end of its recent trading range.

Traders should now look for long-biased trades in Ophthotech if it manages to break out above some near-term overhead resistance levels at $5.14 to $5.28 a share with volume that hits near or above its three-month average action of 2.66 million shares. If that breakout materializes soon, then this stock will set up to re-test or possibly take out its gap-down-day high from last December at $6.48 a share. Any high-volume move above $6.48 will then give this stock a chance to re-fill some of its previous gap-down-day zone that started near $40 a share.

Traders can look to buy this stock off weakness to anticipate that breakout and simply use a stop that sits right around those recent double bottom support levels at $4.66 to $4.53 a share. One can also buy shares of Ophthotech off strength once it starts take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

GoPro

One final under-$10 consumer goods player that's starting to spike within range of triggering a big breakout trade is GoPro (GPRO - Get Report) , which develops and sells mountable and wearable cameras, and accessories in the U.S. and internationally. This stock has been under heavy selling pressure over the last three months, with shares falling sharply by 45.3%.

If you take a glance at the chart for GoPro, you'll notice that this stock recently formed a triple bottom chart pattern, after shares found some buying interest at $8.54, $8.75 and $8.65 a share over the last month. Following that potential bottom, shares of GoPro have now started to spike higher and move back above its 20-day moving average of $8.98 a share. That spike to the upside is now quickly pushing this stock within range of triggering a big breakout trade above some key overhead resistance levels.

Traders should now look for long-biased trades in GoPro if it manages to break out above some near-term overhead resistance levels at $9.50 to $9.60 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 5.33 million shares. If that breakout hits soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $10 to its 50-day moving average of $10.14, or even $10.40 to $11.50 a share.

Traders can look to buy shares of GoPro off weakness to anticipate that breakout and simply use a stop that sits right below its 20-day moving average of $8.98 a share or around those recent triple bottom support levels. One can also buy this stock off strength once it starts to bust above those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.